Void · Condition unmet

At least one US health insurer publishes a coverage policy that covers an FDA-approved botanical marijuana product for the indication on its FDA label.

TRUE on the effective date of the first published coverage policy, medical policy bulletin, formulary listing or fee schedule of a US health insurer, Medicare or a state Medicaid program that covers an FDA-approved botanical (whole-plant or smoked) marijuana product for the indication named on its FDA-approved label. Coverage of cannabinoid drugs that are not botanical marijuana (for example dronabinol, nabilone or a purified cannabidiol product) does not count. Reimbursement under a state medical-marijuana program without FDA approval does not count. Resolution source: the payer's published policy bulletin, with the CMS Medicare Coverage Database for Medicare and Medicaid policies. FALSE at the deadline when no such policy is in effect.

Resolution source: Payer policy bulletins (commercial insurers, state Medicaid); CMS Medicare Coverage Database

Readings: 'Insurance companies will then be willing to cover it as a medicine' is read as at least one US health insurer publishing a coverage policy; no payer is named, so any US health plan counts.; The ledger reads 'plans will cover' as 'a plan covers', as in E-0056.; 'It' is the marijuana that MAPS is studying for PTSD, the subject of the sentence; the label indication at approval sets the covered indication.; 'Particularly if it saves them money on other medicines' is a reason, not a second condition.